Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Care management intervention strategies

11 evidence topics · 17 sources

Management in designated referral centers with a multidisciplinary tumor board
Ovarian toxicity monitoring and fertility counseling
Onset of adverse events with varegacestat in RINGSIDE Part B
Adverse event (varegacestat, N=79)All grades, n (%)Median time to onset (days)
Diarrhea“65 (82.3)”“14.0”
Nausea“28 (35.4)”“8.0”
Rash“56 (70.9)”“24.0”
Fatigue“46 (58.2)”“27.5”
Hypophosphatemia“27 (34.2)”“29.0”
Ovarian toxicity“20 (25.3)”“56.5”
Commercial payer prior authorization criteria for nirogacestat